

**JAYPIRCA
(pirtobrutinib)**

Pre - PA Allowance

None

Prior-Approval Requirements

Age 18 years of age or older

Diagnoses

Patient must have **ONE** of the following:

1. Relapsed or refractory mantle cell lymphoma (MCL)
 - a. Patient has received at least two lines of systemic therapy, including a BTK inhibitor
2. Chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL)
 - a. Patient has received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor

AND ALL of the following:

- a. Prescriber agrees to monitor for infections and malignancies
- b. Prescriber agrees to monitor complete blood count (CBC) for cytopenias
- c. Prescriber agrees to monitor for atrial fibrillation and atrial flutter
- d. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Jaypirca and for 1 week after the last dose

Prior - Approval Limits

Quantity

| Strength | Daily Dosing Limits |
|----------|---------------------|
| 50 mg | 300 mg per day |
| 100 mg | |

Duration 12 months

Prior – Approval *Renewal* Requirements

Age 18 years of age or older

**JAYPIRCA
(pirtobrutinib)**

Diagnoses

Patient must have **ONE** of the following:

1. Relapsed or refractory mantle cell lymphoma (MCL)
2. Chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL)

AND ALL of the following:

- a. **NO** disease progression or unacceptable toxicity
- b. Prescriber agrees to monitor for infections and malignancies
- c. Prescriber agrees to monitor CBC for cytopenias
- d. Prescriber agrees to monitor for atrial fibrillation and atrial flutter
- e. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Jaypirca and for 1 week after the last dose

Prior - Approval *Renewal* Limits

Same as above